Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.58 |
| ▸ | CTNNB1 | P35222 | 5/20 | 0.57 |
| ▸ | WNT3A | P56704 | 5/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | F7 | P08709 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | F3 | P13726 | 1/20 | 0.52 |
| ▸ | AHR | P35869 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7243647 | 0.85 | ALDH1A1 (0.70) | MAPTAHRKDM4EALDH1A1HPGD | |
| SCHEMBL27594531 | 0.84 | TUBB4A (0.67) | F2CTNNB1WNT3ARAB9AMAPT | |
| SCHEMBL6447473 | 0.82 | F2 (0.59) | F2CTNNB1WNT3ARAB9AMAPT | |
| SCHEMBL105928 | 0.82 | KDM4E (0.72) | F2CTNNB1WNT3ARAB9AMAPT | |
| SCHEMBL29540009 | 0.81 | F2 (0.68) | F2CTNNB1WNT3ARAB9AMAPT | |
| Hydrochloric Acid SCHEMBL698541 | 0.81 | KDM4E (0.70) | F2CTNNB1WNT3ARAB9AMAPT | |
| Bromide SCHEMBL6614789 | 0.81 | KDM4E (0.70) | F2CTNNB1WNT3ARAB9AMAPT | |
| SCHEMBL120471 | 0.81 | MAOA (0.66) | F2CTNNB1WNT3ARAB9AMAPT | |
| SCHEMBL19470049 | 0.81 | F2 (0.58) | F2CTNNB1WNT3ARAB9AMAPT | |
| SCHEMBL27968083 | 0.81 | F2 (0.58) | F2CTNNB1WNT3ARAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776971-B2 | Opioid and opioid-like compounds and uses thereof | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2017-10-03 | — | — | US | disclosed |
| CN-103405431-B | Opioid and opioid-like compounds and uses thereof | Taiwan J Pharmaceutical Co.,Ltd. (CN) | 2016-04-13 | — | — | CN | disclosed |
| EP-2987788-A1 | OPIOID AND OPIOID-LIKE COMPOUNDS AND USES THEREOF | Taiwanj Pharmaceuticals Co., Ltd. (TW) | 2016-02-24 | — | — | EP | disclosed |
| EP-1506174-B1 | USE OF NALTREXONE FOR TREATING KIDNEY AND LIVER DAMAGE | TAIWANJ PHARMACEUTICALS CO LTD (TW) | 2015-09-30 | — | — | EP | disclosed |
| CN-103992317-A | Synthesis method of 5-formonitrile-pyrrole [1,2-a ] quinoline derivative | NANJING UNIVERSITY OF TECHNOLOGY | 2014-08-20 | — | — | CN | disclosed |
| CN-103992316-A | Method for synthesizing 5-formonitrile-pyrrole [1,2-a ] quinoline derivative | NANJING UNIVERSITY OF TECHNOLOGY | 2014-08-20 | — | — | CN | disclosed |
| CN-103405431-A | Opioid and opioid-like compounds and uses thereof | JENKEN BIOSCIENCES INC | 2013-11-27 | — | — | CN | disclosed |
| CN-1653050-B | Opioid and opioid-like compounds and uses thereof | JENKEN BIOSCIENCES INC | 2013-04-24 | — | — | CN | disclosed |
| US-8404706-B2 | Opioid and opioid-like compounds and uses thereof | JENKEN BIOSCIENCES, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| CN-102711470-A | Novel tricyclic compounds | ABBOTT LAB | 2012-10-03 | — | — | CN | disclosed |
| US-7501433-B2 | Opioid and opioid-like compounds and uses thereof | JENKEN BIOSCIENCES, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20050261329-A1 | Opioid and opioid-like compounds and uses thereof | JENKEN BIOSCIENCES, INC. | 2005-11-24 | — | — | US | disclosed |
| CN-1653050-A | Opioid and opioid-like compounds and uses thereof | JENKEN BIOSCIENCES INC (US) | 2005-08-10 | — | — | CN | disclosed |
| US-20050107415-A1 | Opioid and opioid-like compounds and uses thereof | JENKEN BIOSCIENCES, INC. | 2005-05-19 | — | — | US | disclosed |
| EP-1506174-A2 | OPIOID AND OPIOID-LIKE COMPOUNDS AND USES THEREOF | Jenken Biosciences, Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097608-A2 | OPIOID AND OPIOID-LIKE COMPOUNDS AND USES THEREOF | JENKEN BIOSCIENCES, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| EP-0700389-A1 | ANTI-ARRHYTHMIC N-SUBSTITUTED 3-BENZAZEPINES OR ISOQUINOLINES | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1996-03-13 | — | — | EP | disclosed |
| EP-0700385-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1996-03-13 | — | — | EP | disclosed |
| WO-1994027967-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1994-12-08 | — | — | WO | disclosed |
| WO-1994027971-A1 | ANTI-ARRHYTHMIC N-SUBSTITUTED 3-BENZAZEPINES OR ISOQUINOLINES | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107415-A1 | Opioid and opioid-like compounds and uses thereof | OPRL1, OPRK1, OPRM1 | F2 2481/4885CTNNB1 3331/4885WNT3A 1200/4885 |
| US-20050261329-A1 | Opioid and opioid-like compounds and uses thereof | OPRK1, OPRL1, OPRM1 | F2 2645/4885CTNNB1 3797/4885WNT3A 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.